PAK6 and melanoma: We also find that a melanoma-associated mutation within the pseudosubstrate sequence, P52L, disrupts PAK6 autoinhibition enhancing its kinase activity, potentially correlating with increased expression of PAK6 in prostate cancer, and implied alterations in kinase activity [15].